David Hutton

According to the company, it is planning to hold an end-of-phase 2 meeting with the FDA to discuss the results.

A University of Houston researcher has been awarded a $1.6 million grant to help restore vision loss in patients with the rare disease that causes blindness.

A team of researchers have found that STOC tomography enables unprecedented views of eye structure.

Company says the products will give its customers more choices and flexibility when considering treatment options for their patients and the specific needs of their practices.

Researchers used obesity as a model to accelerate and exaggerate the stressors experienced by the body throughout life.

According to the FTC, the money will be used to compensate consumers the company allegedly lured with deceptive offers.

The study advances the understanding of the leading cause of visual impairment in adults.

The United States Department of Justice originally filed the lawsuit in December 2021 on behalf of an elderly quadriplegic patient, alleging that Tempe, Arizona-based Barnet Dulaney Perkins Eye Center was requiring patients with mobility disabilities to hire third-party medical transport and transfer assistance for outpatient surgical procedures. American Vision Partners was named as a codefendant.

Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible.

Investigators found that all patients had similar single surgery success rates but that minority patients had significantly worse vision outcomes and were more likely to have multiple retinal breaks.

In a conversation with David Hutton of Ophthalmology Times®, Ferhina S. Ali, MD, MPH, discussed the real world use of faricimab in the IRIS Registry during a presentation this week at Hawaiian Eye in Kauai Hawaii, focusing on the use of faricimab for the treatment of neovascular AMD and diabetic macular edema.

Terms for the deal for AcuFocus were not revealed by the companies.

Diabetic retinopathy is the leading cause of blindness in American adults, and a team of researchers believes the source of this damage may lie in the belly — mainly a leaky small intestine. A novel treatment can possibly prevent or reverse this damage.

A collaborative team of researchers with Oregon Health & Science University and Oregon State University are using lipid nanoparticles to target light-sensitive cells in the eye.

According to the U.S. Attorney’s Office for the Northern District of Georgia, Aarti D. Pandya, MD, settled allegations that she performed and billed for medically unnecessary cataract surgeries and diagnostic tests.

The EyeMobile will visit approximately 250 preschools to provide vision services to low-income families.

Viridian Therapeutics unveils positive data from its ongoing Phase 1/2 trial evaluating low dose VRDN-001 in patients diagnosed with TED.

The study could lead to early diagnosis and treatment of age-related macular degeneration.

According to the company, gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride treatment administered via the company’s microdose formulation decreased inflammation from preserved glaucoma solutions compared to drops.

A study by researchers at Oregon Health & Science University, the University of Chicago, Harvard University and Johns Hopkins University reveals more churn in workforce and greater reliance on physician assistants.

The results from an exchange trial demonstrated a second administration of travoprost intraocular implant and removal of the original implant was safe and well-tolerated, while the company also provided updates for several of its corneal health pipeline programs for the treatment of keratoconus and dry eye disease.

According to the company, it will initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in the first quarter of 2023.

According to the company, the IC-8 Apthera IOL is a wavefront-filtering intraocular lens for unilateral implantation in the non-dominant eye in patients who have as much as 1.5 D of corneal astigmatism in the implanted eye.

The company will add programs in diabetic macular edema and myopia as it completes pre-clinical studies.

BVS Sight Inc. was created through a partnership between Boomerang Ventures and Purdue Research Foundation.

The Alcon Children’s Vision Center is available for follow-up appointments and ongoing eye care, all free of charge for qualified students in need, from Pre-Kindergarten through Grade 12.

According to the company, the launch of the presbyopia phase 3 program is supported by positive clinical results that demonstrated durable efficacy and a favorable safety profile.

NOV03 is being investigated to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction, and a PDUFA action date has been set for June 28.

FT-001 is administered by a one-time injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene to the nuclei of the patient’s retinal cells.